🚀 VC round data is live in beta, check it out!
ALS Valuation Multiples
Discover revenue and EBITDA valuation multiples for ALS and similar public comparables like Qiagen, Pharmaron Beijing, Repligen, Sonic Healthcare and more.
ALS Overview
About ALS
Founded in the 1880s and listing on the ASX in 1952, ALS operates two divisions: commodities and life sciences. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas has lessened earnings exposure to commodities.
Founded
1910
HQ
Employees
20.5K
Website
Sectors
Financials (LTM)
EV
$9B
ALS Financials
ALS reported last 12-month revenue of $2B and EBITDA of $600M.
In the same LTM period, ALS generated $604M in gross profit, $600M in EBITDA, and $273M in net income.
Revenue (LTM)
ALS P&L
In the most recent fiscal year, ALS reported revenue of $2B and EBITDA of $484M.
ALS expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $604M | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $600M | XXX | $484M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $273M | XXX | $201M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ALS Stock Performance
ALS has current market cap of $8B, and enterprise value of $9B.
Market Cap Evolution
ALS's stock price is $15.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $8B | 0.0% | XXX | XXX | XXX | $0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialALS Valuation Multiples
ALS trades at 3.8x EV/Revenue multiple, and 15.2x EV/EBITDA.
EV / Revenue (LTM)
ALS Financial Valuation Multiples
As of April 20, 2026, ALS has market cap of $8B and EV of $9B.
Equity research analysts estimate ALS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ALS has a P/E ratio of 29.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 15.2x | XXX | 18.9x | XXX | XXX | XXX |
| EV/EBIT | 21.2x | XXX | 27.7x | XXX | XXX | XXX |
| EV/Gross Profit | 15.2x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 29.4x | XXX | 40.0x | XXX | XXX | XXX |
| EV/FCF | 62.6x | XXX | 52.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ALS Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ALS Margins & Growth Rates
ALS's revenue in the last 12 month grew by 10%.
ALS's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
ALS's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ALS's rule of X is 53% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ALS Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 55% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ALS Public Comps
See public comps and valuation multiples for other Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ALS | XXX | XXX | XXX | XXX | XXX | XXX |
| Qiagen | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmaron Beijing | XXX | XXX | XXX | XXX | XXX | XXX |
| Repligen | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ALS M&A Activity
ALS acquired XXX companies to date.
Last acquisition by ALS was on XXXXXXXX, XXXXX. ALS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ALS
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialALS Investment Activity
ALS invested in XXX companies to date.
ALS made its latest investment on XXXXXXXX, XXXXX. ALS invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ALS
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ALS
| When was ALS founded? | ALS was founded in 1910. |
| Where is ALS headquartered? | ALS is headquartered in Australia. |
| How many employees does ALS have? | As of today, ALS has over 20K employees. |
| Who is the CEO of ALS? | ALS's CEO is Malcolm Deane. |
| Is ALS publicly listed? | Yes, ALS is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of ALS? | ALS trades under ALQ ticker. |
| When did ALS go public? | ALS went public in 1952. |
| Who are competitors of ALS? | ALS main competitors are Qiagen, Pharmaron Beijing, Repligen, Sonic Healthcare. |
| What is the current market cap of ALS? | ALS's current market cap is $8B. |
| What is the current revenue of ALS? | ALS's last 12 months revenue is $2B. |
| What is the current revenue growth of ALS? | ALS revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of ALS? | Current revenue multiple of ALS is 3.8x. |
| Is ALS profitable? | Yes, ALS is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ALS? | ALS's last 12 months EBITDA is $600M. |
| What is ALS's EBITDA margin? | ALS's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of ALS? | Current EBITDA multiple of ALS is 15.2x. |
| What is the current FCF of ALS? | ALS's last 12 months FCF is $146M. |
| What is ALS's FCF margin? | ALS's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of ALS? | Current FCF multiple of ALS is 62.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.